Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)

Completed

• Conditions: Prostatic Cancer

• Registration Number: NCT01284608
• Lead Sponsor: AstraZeneca

Brief Summary

This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-01-26
• Study First Submitted QC: 2011-01-26
• Study First Posted: 2011-01-27
• Study Start: 2011-03
• Status Verified: 2012-12
• Primary Completion: 2012-12
• Study Completion: 2012-12
• Last Update Submitted: 2012-12-21
• Last Update Posted: 2012-12-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 197

Inclusion Criteria

• Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment
• Provision of informed consent prior to conducting any study-related procedure

Exclusion Criteria

• Patient involved in a Clinical Trial

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Metabolic syndrome	12 months
Diabetes	12 months

Secondary Outcome Measures

Name	Time	Method
Fracture Risk Assessment Tool (FRAx) assessment	0 and 12 months

Trial Locations

Locations (1)

Research Site; 🇪🇸 Zaragoza, Spain